Highlights of This Issue 2593

SPECIAL FEATURES

CCR Translations

2595  Oncolytic Virotherapy Needs Trials, Not Access Programs
      Kevin J. Harrington
      See article, p. 2734

Molecular Pathways

2598  Molecular Pathways: Tumor-Derived Microvesicles and Their Interactions with Immune Cells In Vivo
      Ferdinando Pucci and Mikael J. Pittet

CCR Focus

2606  PFS: The Endpoint We Love and Love to Hate
      Susan E. Bates

2607  Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors
      Ronald L. Korn and John J. Crowley

2613  Missing Data and Measurement Variability in Assessing Progression-Free Survival Endpoint in Randomized Clinical Trials
      Rajeshwari Sridhara, Sumithra J. Mandrekar, and Lori E. Dodd

2621  The Imaging Viewpoint: How Imaging Affects Determination of Progression-Free Survival
      Daniel Carl Sullivan, Lawrence H. Schwartz, and Binsheng Zhao

2629  The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement
      Liza C. Villaruz and Mark A. Socinski

2637  Assessment of Audit Methodologies for Bias Evaluation of Tumor Progression in Oncology Clinical Trials
      Jenny J. Zhang, Lijun Zhang, Huanyu Chen, Anthony J. Murgo, Lori E. Dodd, Richard Pazdur, and Rajeshwari Sridhara

2646  Modeling the Relationship between Progression-Free Survival and Overall Survival: The Phase II/III Trial
      Mary W. Redman, Bryan H. Goldman, Michael LeBlanc, Anne Schott, and Laurence H. Baker

HUMAN CANCER BIOLOGY

2657  Aberrant BAF57 Signaling Facilitates Prometastatic Phenotypes
      Sucharitha Balasubramaniam, Clay E.S. Comstock, Adam Ertel, Kwang Won Jeong, Michael R. Stallicup, Sankar Addya, Peter A. McCue, William F. Ostrander Jr, Michael A. Augello, and Karen E. Knudsen

2668  Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations

CANCER THERAPY: PRECLINICAL

2677  Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor
      Stela Álvarez-Fernández, Maria Jesús Ortiz-Ruiz, Tracy Parrott, Sara Zaknoen, Enrique M. Ocio, Jesús San Miguel, Francis J. Burrows, Azucena Esparios-Ogando, and Atanasio Pandiella

2688  Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAF\(^{V600E}\) Colorectal Cancer
ABOUT THE COVER

This image is taken from a bone metastasis in a patient with stage IV relapsed invasive CDH1 mutated lobular carcinoma of the breast. The tumor was negative for ERBB2 (HER2) amplification (FISH). The targeted next generation sequencing assay used in this study found an ERBB2-GRB7 putative gene fusion that has not been previously reported. The fusion retains the kinase domain of ERBB2 (uniprot.org) which suggests that it could result in ERBB2 activation. The 17q12-21 amplicon which includes both ERBB2 and GRB7 is frequently amplified in breast cancer and preclinical studies suggest that it may be a recombination hotspot. An expression screening study has reported that GRB7 can function as an ERBB2-dependent oncogene. GRB7 encodes an adaptor protein that interacts with ERBB2 and has been shown in a preclinical study to enhance its transformative capacity and increase ERBB2 phosphorylation in fibroblasts. For details, see the article by Ross and colleagues on page 2668 of this issue.